A Molecular Carrier to Transport and Deliver Cisplatin into Endometrial Cancer Cells

Chemical Biology and Drug Design

Volumn 80, Issue 1, 2012, Pages 9-16

  Borrelli, Antonella ^a   Schiattarella, Antonietta ^a   Musella, Alessandra ^a   Mancini, Roberto ^a   Capasso, Clemente ^b   De Luca, Viviana ^b   Carginale, Vincenzo ^b   Sanseverino, Marina ^c   Tornesello, Anna Lucia ^c   Gori, Enrico ^d   Pica, Alessandra ^e   Di Santi, Annalisa ^e   Basile, Filomena ^e   Iacobellis, Francesca ^f   Colacurci, Nicola ^f   Cobellis, Luigi ^f   Mancini, Aldo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^c INBIOS srl   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cisplatin; Leader peptide

Indexed keywords

CISPLATIN; DRUG CARRIER; RECOMBINANT MANGANESE SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ABSORPTION SPECTROPHOTOMETRY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; ENDOMETRIUM CARCINOMA; FEMALE; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG CARRIERS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, ATOMIC; SUPEROXIDE DISMUTASE;

EID: 84862114730     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01337.x     Document Type: Article

References (28)

1. Berek J.S., Hacker N.F. (2000) Practical Gynecologic Oncology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins.
2. Bakkum-Gamez J.N., Gonzalez-Bosquet J., Laack N.N., Mariani A., Dowdy S.C. (2008) Current issues in the management of endometrial cancer. Mayo Clin Proc;83:97-112.
3. ASTEC/EN.5 Study Group (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet;373:137-146.
4. Panici P.B., Basile S., Maneschi F., Alberto Lissoni A., Signorelli M., Scambia G., Angioli R. et al. (2008) Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst;100:1707-1716.
5. Creutzberg C.L., van Putten W.L.J., Koper P.C.M., Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet;355:1404-1411.
6. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., Pearlman A., Maiman M.A., Bell J.G.; Gynecologic Oncology Group (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol;92:744-751.
7. Fleming G.F. (2007) Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol;25:2983-2990.
8. Humber C.E., Tierney J.F., Symonds R.P., Humber C.E., Tierney J.F., Symonds R.P., Collingwood M., Kirwan J., Williams C., Green J.A. (2007) Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol;18:409-420.
9. Carey M.S., Gawlik C., Fung-Kee-Fung M., Chambers A., Oliver T. (2006) Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol;101:158-167.
10. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S. (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol;22:3902-3908.
11. Pectasides D., Xiros N., Papaxoinis G., Pectasides E., Sykiotis C., Koumarianou A., Psyrri A., Gaglia A., Kassanos D., Gouveris P., Panayiotidis J., Fountzilas G., Economopoulos T. (2008) Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol;109:250-254.
12. 2 every 4weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol;98:294-298.
13. Pignata S., Scambia G., Pisano C., Breda E., Di Maio M., Greggi S., Ferrandina G., Lorusso D., Zagonel V., Febbraro A., Riva N., De Rosa V., Gallo C., Perrone F.; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group (2007) A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer;96:1639-1643.
14. Dizon D.S. (2010) Treatment options for advanced endometrial carcinoma. Gynecol Oncol;117:373-381.
15. Chung-man Ho J., Zheng S., Comhair S.A., Farver C., Erzurum S.C. (2001) Differential expression of Manganese superoxide dismutase and catalase in lung cancer. Cancer Res;61:8578-8585.
16. Mancini A., Borrelli A., Schiattarella A., Aloj L., Aurilio M., Morelli F., Pica A. et al. (2008) Biophysical and biochemical characterization of a liposarcoma-derived recombinant MnSOD protein acting as an anticancer agent. Int J Cancer;123:2684-2695.
17. Borrelli A., Schiattarella A., Mancini R., Morelli F., Capasso C., De Luca V., Gori E., Mancini A. (2011) The leader peptide of a human rec. MnSOD as molecular carrier which delivers high amounts of cisplatin into tumor cells inducing a fast apoptosis in vitro. Int J Cancer;128:453-459.
18. Altundag O., Dursun P., Ayhan A. (2010) Emerging drugs in endometrial cancers. Expert Opin Emerg Drugs;15:557-568.
19. Atherton E., Sheppard R.C. (1989) Solid-Phase Peptide Synthesis: A Practical Approach. Oxford UK: IRL Press, Oxford University;15 p.
20. Kates S.A., Albericio F., Carpino L.A. (1997) Coupling reagents and activation. In: Paquette L.A., editor. Methods in Enzimology. 289, 104-26.
21. Robillard M.S., Valentijn A.R.P.M., Meeuwenoord N.J., van der Marel G.A., van Boom J.H., Reedijk J. (2000) The First Solid-Phase Synthesis of a Peptide-Tethered Platinum(II) Complex. Angew Chem Int Ed;39:3096.
22. Welz B. (1983) Atomic Absorption Spectrometry. Weinheim, Germany: Verlag Chemie.
23. Franken N.A.P., Rodermond H.M., Stap J., Haveman J., van Bree C. (2006) Clonogenic assay of cells in vitro. Nat Protoc;1:2315-2319.
24. Yamada Y., Harashima H. (2008) Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev;60:1439-1462.
25. Mukhopadhyay A., Weiner H. (2007) Delivery of drugs and macromolecules to mitochondria. Adv Drug Deliv Rev;59:729-738.
26. Yamada Y., Akita H., Kogure K., Kamiya H., Harashima H. (2007) Mitochondrial drug delivery and mitochondrial disease therapy - an approach to liposome-based delivery targeted to mitochondria. Mitochondrion;7:63-67.
27. Modica-Napolitano J.S., Singh K.K. (2004) Mitochondrial dysfunction in cancer. Mitochondrion;4:755-762.
28. Wang F., Ogasawara M.A., Huang P. (2010) Small mitochondria-targeting molecules as anti-cancer agents. Mol Aspects Med;31:75-92. Review.